MALVERN, Pa., Oct. 14, 2011 - Siemens Healthcare Diagnostics has received FDA clearance for its Neonatal Total Bilirubin (nBili) assay on the RAPIDPoint® 405 Blood Gas Analyzer, with Version 3.7.1 Software. The nBili test offers results in about 60 seconds, benefiting neonatal intensive care unit (NICU) patients. With one small blood sample—only 100 µL—a full range of analytes can be measured at the point of care, including neonatal bilirubin, blood gases, electrolytes, glucose, total hemoglobin and other critical care parameters required to assess critically ill infants.
Elevated levels of bilirubin can lead to a variety of health conditions in infants, including jaundice, which is usually harmless in newborns, and kernicterus, which damages developing brains cells and may lead to serious neurological complications, including brain damage and hearing loss.¹ The Siemens nBili assay on the RAPIDPoint 405 Blood Gas Analyzer is intended to measure the concentration of bilirubin in an infant’s blood as an aid for assessing the risk for kernicterus in a point-of-care setting.
For more information on Siemens nBili test, visit http://www.medical.siemens.com/siemens/en_GLOBAL/gg_diag_FBAs/files/POC/Blood_Gas/Whole_Blood_Neonatal_Bilirubin_Method.pdf
¹http://www.nlm.nih.gov/medlineplus/ency/article/007309.htm, Medline Plus, Kernicterus
CONTACT
Susan Drew
(914) 524-2844
[email protected]